Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 4, 2015, Pages 1057-1064

  Gu, Hongjing ^a   Li, Tieling ^b   Han, Lina ^b   Zhu, Ping ^a,c   Zhang, Peirui ^d   Zhang, Shaogeng ^d   Sun, Sujing ^a   Duan, Yueqiang ^a   Xing, Li ^a   Zhao, Zhongpeng ^a   Lai, Chengcai ^a   Wen, Bohai ^a   Wang, Xiliang ^a   Yang, Penghui ^a,d  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c NINGXIA MEDICAL UNIVERSITY   (China)

^d 302 MILITARY HOSPITAL   (China)

Author keywords

Intranasal vaccination; RSV; RSV virus like particle vaccine

Indexed keywords

UNCLASSIFIED DRUG; VIRUS ATTACHMENT PROTEIN; VIRUS FUSION PROTEIN; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LUNG INJURY; MOUSE; MUCOSAL IMMUNITY; NEWCASTLE DISEASE; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SUCROSE DENSITY GRADIENT CENTRIFUGATION; VACCINATION; VIRUS ATTACHMENT; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84945190305     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1011993     Document Type: Article

References (27)

1. Mejias A, Chavez-Bueno S, Jafri HS, Ramilo O. Respiratory syncytial virus infections: old challenges and new opportunities. Pediatr Infect Dis J 2005; 24:S189-96, discussion S96-7; PMID:16378045; http://dx. doi. org/ 10. 1097/01. inf. 0000188196. 87969. 9a
2. Stokes KL, Currier MG, Sakamoto K, Lee S, Collins PL, Plemper RK, Moore ML. The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection. J Virol 2013; 87:10070-82; PMID:23843644; http://dx. doi. org/10. 1128/JVI. 01347-13
3. Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev Vaccines 2011; 10:1415- 33; PMID:21988307; http://dx. doi. org/10. 1586/ erv. 11. 120
4. Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: past, present, and future. Pediatr Pulmonol 2011; 46:324-47; PMID:21438168; http://dx. doi. org/10. 1002/ppul. 21377
5. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines 2010; 9:1149-76;PMID:20923267; http://dx. doi. org/10. 1586/erv. 10. 115
6. Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG. Newcastle disease virus-like particles containing respiratory syncytial virusG protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 2010; 84:1110-23; PMID:19889768; http://dx. doi. org/10. 1128/JVI. 01709-09
7. Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 2011; 204:987-95; PMID:21881112; http://dx. doi. org/10. 1093/infdis/ jir474
8. Mena JA, Kamen AA. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev Vaccines 2011; 10:1063-81; PMID:21806400; http://dx. doi. org/10. 1586/erv. 11. 24
9. Deschuyteneer M, Elouahabi A, Plainchamp D, Plisnier M, Soete D, Corazza Y, Lockman L, Giannini S, Deschamps M. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccines 2010; 6:407-19; PMID:20953154; http://dx. doi. org/10. 4161/hv. 6. 5. 11023
10. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003; 21:3465-7; PMID:12850361; http://dx. doi. org/ 10. 1016/S0264-410X(03)00352-9
11. Singh SR, Dennis VA, Carter CL, Pillai SR, Jefferson A, Sahi SV, Moore EG. Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 2007; 25:6211-23; PMID: 17629376; http://dx. doi. org/10. 1016/j. vaccine. 2007. 05. 068
12. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/ Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy-a review. Virus Genes 2006; 33:235-52; PMID:16972040
13. Wahl M, Hermodsson S. Intradermal, subcutaneous or intramuscular administration of hepatitis B vaccine: side effects and antibody response. Scand J Infect Dis 1987; 19:617-21; PMID:3441747; http://dx. doi. org/ 10. 3109/00365548709117195
14. Brandtzaeg P. Induction of secretory immunity andmemory at mucosal surfaces. Vaccine 2007; 25:5467-84; PMID:17227687; http://dx. doi. org/10. 1016/j. vaccine. 2006. 12. 001
15. Corthesy B. Role of secretory IgA in infection and maintenance of homeostasis. Autoimmu Rev 2013; 12:661-5; PMID:23201924; http://dx. doi. org/ 10. 1016/j. autrev. 2012. 10. 012
16. van Riet E, Ainai A, Suzuki T, Hasegawa H. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine 2012; 30:5893-900; PMID:22835738; http://dx. doi. org/10. 1016/j. vaccine. 2012. 04. 109
17. Patel H, Yewale C, Rathi MN, Misra A. Mucosal immunization: a review of strategies and challenges. Crit Rev Ther Drug Carrier Syst 2014; 31:273-303; PMID:25072196; http://dx. doi. org/10. 1615/CritRev TherDrugCarrierSyst. 2014010102
18. Kupsch J, Saizawa KM, Eichmann K. Expression of murine soluble CD4 protein in baculovirus infected insect cells. Immunobiology 1992; 186:254-67; PMID:1490731; http://dx. doi. org/10. 1016/S0171- 2985(11)80255-X
19. Rudan I, O'Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, Luksic I, Fischer Walker CL, Black RE, Campbell H, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health 2013; 3:010401; PMID:23826505; http://dx. doi. org/ 10. 7189/jogh. 03. 010101
20. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum Vaccines 2010; 6:482- 92; PMID:20671419; http://dx. doi. org/10. 4161/ hv. 6. 6. 11562
21. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, et al. Proof of principle for epitope-focused vaccine design. Nature 2014; 507:201-6; PMID:24499818; http://dx. doi. org/ 10. 1038/nature12966
22. McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 2011; 85:366-77; PMID:20980510; http://dx. doi. org/ 10. 1128/JVI. 01861-10
23. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006; 78:1493-7; PMID:16998887; http://dx. doi. org/10. 1002/jmv. 20724
24. Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev 1999; 12:298-309; PMID:10194461
25. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 1992; 89:6901-5; PMID:1323121; http://dx. doi. org/10. 1073/pnas. 89. 15. 6901
26. Bian C, Liu S, Liu N, Zhang G, Xing L, Song Y, Duan Y, Gu H, Zhou Y, Zhang P, et al. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice. Antiviral Res 2014; 104:110- 7; PMID:24509239; http://dx. doi. org/10. 1016/j. antiviral. 2014. 01. 022
27. Gao X, Wang W, Li Y, Zhang S, Duan Y, Xing L, Zhao Z, Zhang P, Li Z, Li R, et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge. Antiviral Res 2013; 98:4-11; PMID:23416215; http://dx. doi. org/10. 1016/j. antiviral. 2013. 01. 010